{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:42:39Z","timestamp":1786981359425,"version":"build-2736575974"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T00:00:00Z","timestamp":1708473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T00:00:00Z","timestamp":1708473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Clin Immunol"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s10875-024-01672-2","type":"journal-article","created":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T02:02:20Z","timestamp":1708480940000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Neuropathologic Impacts of JAK Inhibitor Treatment in Aicardi-Gouti\u00e8res Syndrome"],"prefix":"10.1007","volume":"44","author":[{"given":"Saba","family":"Jafarpour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolee","family":"Suddock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra","family":"Hawes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan D.","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,21]]},"reference":[{"issue":"4","key":"1672_CR1","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1086\/521373","volume":"81","author":"G Rice","year":"2007","unstructured":"Rice G, et al. Clinical and molecular phenotype of Aicardi-Goutieres syndrome. Am J Hum Genet. 2007;81(4):713\u201325.","journal-title":"Am J Hum Genet"},{"issue":"10","key":"1672_CR2","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1056\/NEJMc2001362","volume":"383","author":"A Vanderver","year":"2020","unstructured":"Vanderver A, et al. Janus Kinase Inhibition in the Aicardi-Gouti\u00e8res Syndrome. N Engl J Med. 2020;383(10):986\u20139.","journal-title":"N Engl J Med"},{"issue":"12","key":"1672_CR3","doi-asserted-by":"publisher","first-page":"e75","DOI":"10.1136\/annrheumdis-2016-210504","volume":"75","author":"MP Rodero","year":"2016","unstructured":"Rodero MP, et al. JAK inhibition in STING-associated interferonopathy. Ann Rheum Dis. 2016;75(12):e75.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1672_CR4","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1136\/annrheumdis-2016-209841","volume":"76","author":"N K\u00f6nig","year":"2017","unstructured":"K\u00f6nig N, et al. Familial chilblain lupus due to a gain-of-function mutation in STING. Ann Rheum Dis. 2017;76(2):468\u201372.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1672_CR5","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/j.jaci.2016.07.015","volume":"138","author":"ML Fr\u00e9mond","year":"2016","unstructured":"Fr\u00e9mond ML, et al. Efficacy of the Janus kinase 1\/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children. J Allergy Clin Immunol. 2016;138(6):1752\u20135.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"1672_CR6","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1007\/s10875-023-01500-z","volume":"43","author":"ML Fr\u00e9mond","year":"2023","unstructured":"Fr\u00e9mond ML, et al. JAK inhibition in Aicardi-Gouti\u00e8res Syndrome: a Monocentric Multidisciplinary Real-World Approach Study. J Clin Immunol. 2023;43(6):1436\u201347.","journal-title":"J Clin Immunol"},{"issue":"2","key":"1672_CR7","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ymgme.2020.03.008","volume":"130","author":"LA Adang","year":"2020","unstructured":"Adang LA, et al. Development of a neurologic severity scale for Aicardi Gouti\u00e8res Syndrome. Mol Genet Metab. 2020;130(2):153\u201360.","journal-title":"Mol Genet Metab"},{"issue":"6","key":"1672_CR8","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1177\/1093526619837797","volume":"22","author":"A Gilani","year":"2019","unstructured":"Gilani A, et al. Neuropathological findings in a case of IFIH1-Related Aicardi-Gouti\u00e8res Syndrome. Pediatr Dev Pathol. 2019;22(6):566\u201370.","journal-title":"Pediatr Dev Pathol"},{"key":"1672_CR9","doi-asserted-by":"crossref","unstructured":"Barth PG. The neuropathology of Aicardi-Gouti\u00e8res syndrome Eur J Paediatr Neurol, 2002. 6 Suppl A: p. A27-31; discussion A37-9, A77-86.","DOI":"10.1053\/ejpn.2002.0570"},{"issue":"5","key":"1672_CR10","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/ajmg.a.37577","volume":"170a","author":"F Marguet","year":"2016","unstructured":"Marguet F, et al. Clinical and pathologic features of Aicardi-Gouti\u00e8res syndrome due to an IFIH1 mutation: a pediatric case report. Am J Med Genet A. 2016;170a(5):1317\u201324.","journal-title":"Am J Med Genet A"},{"issue":"6","key":"1672_CR11","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1212\/WNL.0000000000004921","volume":"90","author":"K Kothur","year":"2018","unstructured":"Kothur K, et al. An open-label trial of JAK 1\/2 blockade in progressive IFIH1-associated neuroinflammation. Neurology. 2018;90(6):289\u201391.","journal-title":"Neurology"},{"key":"1672_CR12","doi-asserted-by":"publisher","first-page":"825367","DOI":"10.3389\/fimmu.2022.825367","volume":"13","author":"W Li","year":"2022","unstructured":"Li W, et al. Janus Kinase Inhibitors in the treatment of type I interferonopathies: a Case Series from a single Center in China. Front Immunol. 2022;13:825367.","journal-title":"Front Immunol"},{"key":"1672_CR13","doi-asserted-by":"publisher","first-page":"725868","DOI":"10.3389\/fped.2021.725868","volume":"9","author":"M Cattalini","year":"2021","unstructured":"Cattalini M, et al. Case Report: the JAK-Inhibitor Ruxolitinib Use in Aicardi-Goutieres Syndrome due to ADAR1 mutation. Front Pediatr. 2021;9:725868.","journal-title":"Front Pediatr"},{"issue":"8","key":"1672_CR14","doi-asserted-by":"publisher","first-page":"e7724","DOI":"10.1002\/ccr3.7724","volume":"11","author":"J Galli","year":"2023","unstructured":"Galli J, et al. Treatment response to Janus kinase inhibitor in a child affected by Aicardi-Gouti\u00e8res syndrome. Clin Case Rep. 2023;11(8):e7724.","journal-title":"Clin Case Rep"},{"issue":"2","key":"1672_CR15","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/dmcn.15025","volume":"64","author":"VX Han","year":"2022","unstructured":"Han VX, et al. Cerebrospinal fluid neopterin as a biomarker of treatment response to Janus kinase inhibition in Aicardi-Gouti\u00e8res syndrome. Dev Med Child Neurol. 2022;64(2):266\u201371.","journal-title":"Dev Med Child Neurol"},{"issue":"22","key":"1672_CR16","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1056\/NEJMc2031081","volume":"383","author":"B Neven","year":"2020","unstructured":"Neven B, et al. JAK inhibition in the Aicardi-Gouti\u00e8res Syndrome. N Engl J Med. 2020;383(22):2190\u20131.","journal-title":"N Engl J Med"},{"key":"1672_CR17","unstructured":"Committee for Medicinal Products for Human Use, European Medicines Agency Assessment report: Olumiant 2016."}],"container-title":["Journal of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-024-01672-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10875-024-01672-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-024-01672-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T07:16:14Z","timestamp":1713856574000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10875-024-01672-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,21]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["1672"],"URL":"https:\/\/doi.org\/10.1007\/s10875-024-01672-2","relation":{},"ISSN":["0271-9142","1573-2592"],"issn-type":[{"value":"0271-9142","type":"print"},{"value":"1573-2592","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,21]]},"assertion":[{"value":"27 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"68"}}